I
Ines Elakhal Naouar
Researcher at Henry M. Jackson Foundation for the Advancement of Military Medicine
Publications - 3
Citations - 59
Ines Elakhal Naouar is an academic researcher from Henry M. Jackson Foundation for the Advancement of Military Medicine. The author has contributed to research in topics: Neutralizing antibody & Vaccination. The author has an hindex of 2, co-authored 3 publications receiving 20 citations. Previous affiliations of Ines Elakhal Naouar include Walter Reed Army Institute of Research.
Papers
More filters
Posted ContentDOI
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
Michael Gordon Joyce,Michael Gordon Joyce,Hannah A.D. King,Hannah A.D. King,Ines Elakhal Naouar,Aslaa Ahmed,Kristina K. Peachman,Camila Macedo Cincotta,Caroline Subra,Rita E. Chen,Paul V. Thomas,Paul V. Thomas,Wei-Hung Chen,Wei-Hung Chen,Rajeshwer S. Sankhala,Rajeshwer S. Sankhala,Agnes Hajduczki,Agnes Hajduczki,Elizabeth J. Martinez,Elizabeth J. Martinez,Caroline E. Peterson,Caroline E. Peterson,William C. Chang,William C. Chang,Misook Choe,Misook Choe,Clayton Smith,Parker J. Lee,Parker J. Lee,Jarrett A. Headley,Jarrett A. Headley,Mekdi G. Taddese,Mekdi G. Taddese,Hanne A. Elyard,Anthony L. Cook,Alexander R. A. Anderson,Alexander R. A. Anderson,Kathryn McGuckin-Wuertz,Ming Dong,Ming Dong,Isabella Swafford,Isabella Swafford,James B. Case,Jeffrey R. Currier,Kerri G. Lal,Kerri G. Lal,Sebastian Molnar,Sebastian Molnar,Manoj S. Nair,Vincent Dussupt,Vincent Dussupt,Sharon P. Daye,Xiankun Zeng,Erica K. Barkei,Hilary M. Staples,Kendra J. Alfson,Ricardo Carrion,Shelly J. Krebs,Shelly J. Krebs,Dominic Paquin-Proulx,Dominic Paquin-Proulx,Nicos Karasavva,Victoria R. Polonis,Linda L. Jagodzinski,Mihret F. Amare,Mihret F. Amare,Sandhya Vasan,Sandhya Vasan,Paul T. Scott,Yaoxing Huang,David D. Ho,Natalia de Val,Michael S. Diamond,Mark G. Lewis,Mangala Rao,Gary R. Matyas,Gregory D. Gromowski,Sheila A. Peel,Nelson L. Michael,Diane L. Bolton,Diane L. Bolton,Kayvon Modjarrad +81 more
TL;DR: In this paper, a Spike protein ferritin nanoparticle (SpFN) vaccine was developed and evaluated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in nonhuman primates.
Posted ContentDOI
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Hannah A.D. King,Hannah A.D. King,M. Gordon Joyce,Ines Elakhal Naouar,Aslaa Ahmed,Camila Macedo Cincotta,Caroline Subra,Caroline Subra,Kristina K. Peachman,Holly H Hack,Rita E. Chen,Paul V. Thomas,Wei-Hung Chen,Rajeshwer S. Sankhala,Agnes Hajduczki,Elizabeth J. Martinez,Caroline E. Peterson,William C. Chang,Misook Choe,Clayton Smith,Jarrett A. Headley,Hanne A. Elyard,Anthony L. Cook,Alexander R. A. Anderson,Alexander R. A. Anderson,Kathryn McGuckin Wuertz,Ming Dong,Ming Dong,Isabella Swafford,Isabella Swafford,James Brett Case,Jeffrey R. Currier,Kerri G. Lal,Kerri G. Lal,Mihret F. Amare,Vincent Dussupt,Vincent Dussupt,Sebastian Molnar,Sebastian Molnar,Sharon P. Daye,Xiankun Zeng,Erica K. Barkei,Kendra J. Alfson,Hilary M. Staples,Ricardo Carrion,Shelly J. Krebs,Shelly J. Krebs,Dominic Paquin-Proulx,Dominic Paquin-Proulx,Nicos Karasavvas,Victoria R. Polonis,Linda L. Jagodzinski,Sandhya Vasan,Sandhya Vasan,Paul T. Scott,Yaoxing Huang,Manoj S. Nair,David D. Ho,Natalia de Val,Michael S. Diamond,Mark G. Lewis,Mangala Rao,Gary R. Matyas,Gregory D. Gromowski,Sheila A. Peel,Nelson L. Michael,Kayvon Modjarrad,Diane L. Bolton,Diane L. Bolton +68 more
TL;DR: In this article, the SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) was evaluated in a nonhuman primate challenge model that addresses the need for a next generation, efficacious vaccine with increased pan-SARS breadth of coverage.
Posted ContentDOI
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
Kathryn McGuckin Wuertz,Erica K. Barkei,Wei-Hung Chen,Wei-Hung Chen,Elizabeth J. Martinez,Elizabeth J. Martinez,Ines Elakhal Naouar,Ines Elakhal Naouar,Linda L. Jagodzinski,Dominic Paquin-Proulx,Dominic Paquin-Proulx,Gregory D. Gromowski,Isabella Swafford,Isabella Swafford,Akshaya Ganesh,Akshaya Ganesh,Ming Dong,Ming Dong,Xiankun Zeng,Paul V. Thomas,Paul V. Thomas,Rajeshwer S. Sankhala,Rajeshwer S. Sankhala,Agnes Hajduczki,Agnes Hajduczki,Caroline E. Peterson,Caroline E. Peterson,Caitlin Kuklis,Sandrine Soman,Lindsey Wieczorek,Lindsey Wieczorek,Michelle Zemil,Michelle Zemil,Alexander R. A. Anderson,Alexander R. A. Anderson,Janice Darden,Janice Darden,Heather Hernandez,Heather Hernandez,Hannah Grove,Hannah Grove,Vincent Dussupt,Vincent Dussupt,Holly R. Hack,Holly R. Hack,Rafael De La Barrera,Stasya Zarling,James F. Wood,Jeffrey W. Froude,Matthew Gagne,Amy R. Henry,Elyham Bayat Mokhtari,Prakriti Mudvari,Shelly J. Krebs,Shelly J. Krebs,Andrew Pekosz,Jeffrey R. Currier,Swagata Kar,Marciel Porto,Adrienne Winn,Kamil Radzyminski,Mark G. Lewis,Sandhya Vasan,Mehul S. Suthar,Victoria R. Polonis,Gary R. Matyas,Eli Boritz,Daniel C. Douek,Robert A. Seder,Sharon P. Daye,Mangala Rao,Sheila A. Peel,M. Gordon Joyce,M. Gordon Joyce,Diane L. Bolton,Diane L. Bolton,Nelson L. Michael,Kayvon Modjarrad +77 more
Abstract: The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) immunogen dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose two vaccinations. SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.